Wyniki wyszukiwania:

An estimated 80 million people live with a neurodegenerative disease. That number is expected to increase rapidly as populations age, lifespans increase, and exposure to toxins rises. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases. This is because diseases such as Parkinson's and Alzheimer's do not exist in biology. Yet, hundreds of clinical trials around the world are examining the potential of single therapies in thousands of people sharing one of these labels. Compounding the problem, these...

Slowness of movement ("bradykinesia") is the most important deficit in Parkinsons disease (PD). Current clinical rating of bradykinesia in PD does not separate the dimensions of slowness and amplitude reduction. We categorized patterns of movement in PD patients on a biaxial classification of speed and amplitude using an electromagnetic tracking device (Polhemus) seeking to determine whether these categories may differentially contribute to motor impairment and disability. Motor impairment was worst in patients with very impaired amplitude and best in patients with normal ...